Close Menu

City of Hope

The team will launch a Phase II study to validate early-stage gastric cancer micro-RNA biomarkers and eventually develop liquid biopsy tests.

In PNAS this week: study of central nervous system inflammation roots, circulating immune cells in cancer reflect patient response to treatment, and more.

The approach is essentially a simplified version of the technology in Fluidigm's CyTOF instruments, using metal-linked antibodies to measure proteins.

An analysis in JAMA Network Open examines regulatory approvals not based on randomized clinical trials.

The program, launched last year, is designed to help early-career investigators who have primarily worked within groups pursuing independent research.

The group believes that being able to track ctDNA changes down to the lowest possible levels may be necessary for liquid biopsy to monitor treatment in early-stage cancers.

City of Hope and Texas Oncology are the first customers for Trapelo, a decision support platform from Innovation Insights that involves labs and payors.

DxTerity aims to develop a genomic blood test to identify which cancer patients are most likely to benefit from radiation therapy or are at risk for toxicity.

In PNAS this week: analytical method for assessing shared variants, treatment targets in hereditary pancreatic cancer, and more.

In individuals diagnosed with prostate cancer before the age of 45, researchers saw enhanced expression of immune- and inflammation-related genes.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.